title: The effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the disease.
abstract: Zoledronic acid has shown indirect anticancer effects on angiogenesis, the tumor microenvironment and immune responses. Its immunological action is exerted, at least in part, via its modulating properties. The aim of this study was to investigate the in vitro effects of zoledronic acid on the dendritic cells of melanoma patients. Peripheral blood samples were collected from 26 patients with melanoma and 11 healthy donors. Dendritic cells were derived from purified monocytes, and zoledronic acid (ZA) was added on the first day of culture. The phenotype and function of the generated cells were evaluated by flow cytometry. The ZA-treated monocytes from patients with early-stage disease generated DCs characterized by reduced endocytic activity and increased allostimulatory capacity compared with the untreated samples, allowing restoration of the DC function observed in normal subjects. In contrast, the ZA-treated monocytes from patients at stage III generated cells with higher CD14 antigen expression and endocytosis than the untreated samples. Therefore, in melanoma patients, the in vitro ZA effects differ according to the progression of the disease. In addition, our preliminary results appear to suggest that ZA effects are also influenced by the expression of CD14 antigen, indicating that the DC phenotype together with clinical characteristics must be considered in the choice of patients to be treated with ZA. Our work focus on the effect of ZA on monocyte-derived DCs from melanoma patients, showing that the effects of therapeutic doses of this drug might be mediated at least in part by modulation of myeloid cell function.
authors.affiliation: a Department of Clinical and Experimental Medicine ; University of Pisa ; Pisa , Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Failli
authors.forename: Annalisa
authors.initials: A
authors.lastname: Legitimo
authors.forename: Giulia
authors.initials: G
authors.lastname: Orsini
authors.forename: Antonella
authors.initials: A
authors.lastname: Romanini
authors.forename: Rita
authors.initials: R
authors.lastname: Consolini
mesh_terms: D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D004164:Diphosphonates / Q000627:therapeutic use*; D018450:Disease Progression; D004705:Endocytosis / Q000187:drug effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D059016:Tumor Microenvironment / Q000187:drug effects; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D018950:Lipopolysaccharide Receptors; D000077211:Zoledronic Acid
keywords: dendritic cells; melanoma; zoledronic acid